• Overview of Thyroid Eye Disease Pathophysiology
• Clinical Features: Improving Diagnosis
• Current and Emerging Therapeutic Landscape
• Question and Answer

Upon successful completion of the activities, participants should be better able to:

• Describe the basic pathophysiology of Graves’ disease and thyroid eye disease.
• Analyze early signs and symptoms of thyroid eye disease, including criteria for stratifying mild, moderate, and severe disease, and determinants of disease activity.
• Evaluate new and emerging biological agents for treatment of thyroid eye disease.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Terry J. Smith, MD - Program Chair
Frederick G.L. Huetwell Professor 
Ophthalmology and Visual Sciences 
Professor of Internal Medicine 
University of Michigan Medical School 
Ann Arbor, Michigan 

Don O. Kikkawa, MD 
Chief, Division of Oculofacial Plastic and Reconstructive Surgery 
Professor of Ophthalmology 
Vice-Chairman, Department of Ophthalmology 
University of California San Diego 
La Jolla, CA

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Don O. Kikkawa, MD: Consultant, Horizon Therapeutics; Book Royalties, Elsevier Publishing
Terry J. Smith, MD:  Consultant, Novartis, Merck, Lithera, Immunovant, River Vision, Horizon Therapeutics

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences

The following SPC Committee members reported relevant financial relationships:
Andjela T. Drincic, MD: Advisory Board Member, Corcept
Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
Amy Rothberg, MD: Spouse, consultant of Merck

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:
Katherine Araque, MD; Beret Ann Casey, MD; Jenny Blau, MD; Lorena Alarcon-Casas Wright, MD, Neena Natt, MD;Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by an independent medical educational grant from Horizon Therapeutics.